Ivabradine | Placebo | Odds ratio | P-value | I2 in % | |||
---|---|---|---|---|---|---|---|
Outcome | Event/Total, n/N | % | Event/total | % | M-H, random & Fixedb, 95% CI | ||
Cardiovascular death | 1247/18270 | 6.8 | 1227/18254 | 6.7 | 1.02(0.91–1.15) | 0.74 | 51 |
All-cause mortality | 1560/18270 | 8.5 | 1557/18254 | 8.5 | 1(0.91–1.10) | 0.98 | 78 |
Hospital admissiona | 1156/18270 | 6.3 | 1280/18254 | 7 | 0.94(0.71–1.25) | 0.69 | 89 |
Coronary revascularization | 717/15029 | 4.7 | 750/14990 | 5 | 0.93(0.77–1.11) | 0.41 | 57 |
Phosphenes | 601/12771 | 4.7 | 69/12804 | 5.3 | 7.77(4.4–14.6) | <0.00001 | 78 |
Symptomatic bradycardia | 907/12771 | 7.1 | 142/12804 | 1.1 | 6.23(4.2–9.26) | <0.00001 1 | 71 |
Atrial fibrillation | 814/12771 | 6.3 | 613/12804 | 4.7 | 1.35(1.21–1.51) | <0.00001 | 22 |
Blurred vision | 134/12771 | 1 | 44/12804 | 0.3 | 3.07(2.18–4.32) | <0.00001 | 0 |
Infection& infestation | 519/8709 | 5.9 | 555/8690 | 6.3 | 0.93(0.82–1.05) | 0.26 | 0 |
Serious adverse event | 2683/8709 | 31 | 2792/8690 | 32 | 0.97(0.85–1.11) | 0.36 | 48 |
Cardiac disorder | 2203/8709 | 2.5 | 2454/8690 | 2.8 | 0.85(0.65–1.11) | 0.24 | 89 |